protac cdk9 ligand 1

PROTAC CDK9 ligand-1, a CDK9 ligand, is used in the synthesis of PROTACs.

CDK9-IN-11 is a potent CDK9 inhibitor and serves as the ligand for the PROTAC CDK9 Degrader-1 [1].

LC3B ligand 1 is the target protein ligand for PROTAC, and it can be utilized in the synthesis of PROTACCDK9 autophagic degrader 1.

KI-ARv-03 is a potent and selective ATP-competitive CDK9 inhibitor with an IC50 of 0.15 μM (in the presence of 45 μM ATP), demonstrating over 130-fold selectivity for CDK9 over other CDKs (including CDK1-7). It reduces AR-driven transcription and proliferation in prostate cancer cells and is applicable for research on leukemia, pancreatic cancer, alveolar rhabdomyosarcoma (ARMS), and castration-resistant prostate cancer (CRPC). Additionally, KI-ARv-03 serves as a ligand for target protein for PROTAC and is used in the synthesis of PROTAC KI-CDK9d-32[1][2].

PROTAC CDK9 Degrader-1 is a selective PROTAC CDK9 degrader composed of a cereblon ligand and a CDK9 ligand.

PROTAC CDK9/CycT1 Degrader-1 (compounds 10), a potent CDK9 inhibitor and target protein ligand for PROTAC synthesis, exhibits substantial anti-proliferative activity in solid tumors [1], making it instrumental in the targeted degradation of CDK9/CycT1.